Business Wire

Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing ...
Healio

Study yields 'encouraging' preliminary data for navitoclax combination in myelofibrosis

Please provide your email address to receive an email when new articles are posted on . Navitoclax plus ruxolitinib led to improvement in spleen volume reduction in patients with untreated ...
Benzinga.com

Small Cap-MeiraGTx Reveals Encouraging Data From Parkinson's Study Showing Significant, Clinically Meaningful Changes in Key Efficacy Endpoints

On Tuesday, MeiraGTx Holdings plc (NASDAQ:MGTX) released topline data from its clinical bridging study of AAV-GAD for Parkinson’s disease, MGT-GAD-025. MGT-GAD-025 is a 6-month, three-arm, randomized, ...